Wednesday, November 1, 2017

Guest Post from Sandro Santagata, MD, PhD: Papillary Craniopharyngioma Trial

I am pleased to present a guest post from Dr. Sandro Santagata of Brigham and Women’s Hospital/Dana Farber Cancer Center, who writes:



Our group of collaborators has recently opened a Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas that is sponsored by the Alliance for Clinical Trials in Oncology.

The eligibility criteria are listed here: https://clinicaltrials.gov/ct2/show/NCT03224767

The trial is based on work published in these two papers:


I am happy to answer any questions that our colleagues may have about this trial.  ssantagata@bics.bwh.harvard.edu

No comments: